In the realm of cancer therapeutics targeting metabolism, CB-839, a small molecule inhibitor specifically designed to target glutaminase (GLS), strategically manipulate the reliance of cancer cells on glutamine, is noteworthy [33, 34]. This evidence concerns the gene GLS and cancer.